Espero Pharmaceuticals Receives FDA Approval for GONITRO™ (Nitroglycerin) Sublingual Powder

JACKSONVILLE, Fla. (June 14, 2016) – Espero Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved GONITRO™ (nitroglycerin) sublingual powder for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. With this approval, GONITRO™ is the first and only short-acting nitrate in a …

Armetheon and Lee’s Pharma Enter into Agreement to Develop and Commercialize Tecarfarin in Greater China and Thailand

MILPITAS, Calif. and HONG KONG, Sept. 22, 2015 /PRNewswire/ – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Armetheon and China Cardiovascular Focus Limited, a subsidiary of Lee’s Pharmaceutical Holdings Limited (Lee’s Pharma), a public biopharmaceutical company listed on the main board of Hong Kong Stock Exchange (stock code: 950) with an …

Espero Pharmaceuticals Closes Seed Funding Round

JACKSONVILLE, FL – Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the closing of a private round of funding as well as an equity investment made by G. Pohl-Boskamp GmbH & Co. KG (Pohl-Boskamp), a fully-integrated German pharmaceutical company with a 175 year operating history. Espero will use the proceeds to initiate commercialization activities as well …

Fierce Biotech: Armetheon raises $24M to get its anticoagulant into Phase III

By Damian Garde February 5, 2015 Menlo Park, CA’s Armetheon raised a $24.3 million B round to support work on a new oral blood thinner the biotech believes can fill a hole in the blockbuster anticoagulant market. The drug, tecarfarin, works by blocking an enzyme called VKOR that plays a role in blood clotting. In its Phase II trials, the …

Armetheon Completes $7.0 Million Series A Financing

Company poised to enter final pivotal trial for novel oral anti-coagulant Menlo Park, CA, August 28, 2014 –  Armetheon, Inc. (www.armetheon.com), a biopharmaceutical company focused on developing novel mid- to late-stage cardiovascular drug candidates, today announced that it has raised $7.0 million in its first round of financing. The Series A round was co-led by AshHill Biomedical Investments and Hercules Bioventures with …